Previous 10 | Next 10 |
CAMBRIDGE, Mass. , Aug. 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in the following upcoming investor...
Shares of Deciphera Pharmaceuticals (DCPH) have risen by just 1% since my September 2018 article suggested initiating a pilot position in the near term and accumulating weakness. To be fair, I had thought ESMO data for DCC-2618 would boost shares and instead they lost nearly half their value...
Geron (NASDAQ: GERN ) initiated with Overweight rating and $4 (210% upside) price target at Cantor Fitzgerald. Shares up 2% premarket. More news on: Geron Corporation, Blueprint Medicines Corporation, Elanco Animal Health Incorporated, Healthcare stocks news, Stocks on the move...
The FDA accepts for review Blueprint Medicines' ( BPMC +1.2% ) marketing application seeking approval to use avapritinib to treat adult patients with PDGFRA Exon 18-mutant gastrointestinal stromal tumors (GIST), regardless of prior therapy, and fourth-line GIST. The agency's action date ...
CAMBRIDGE, Mass. , Aug. 7, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted the com...
CAMBRIDGE, Mass. , Aug. 6, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Andy Boral , M.D., Ph.D., Blueprint Medicines' ...
Blueprint Medicines Corp (BPMC) Q2 2019 Earnings Conference Call August 01, 2019, 08:30 ET Company Participants Kristin Hodous - Senior Manager, IR Jeffrey Albers - CEO, President & Director Christina Rossi - Chief Commercial Officer Michael Landsittel - CFO Anthony Boral...
Blueprint Medicines (NASDAQ: BPMC ): Q2 GAAP EPS of -$2.04 misses by $0.09 . More news on: Blueprint Medicines Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
CAMBRIDGE, Mass. , Aug. 1, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the quarter ...
AAON , AAWW , ABC , ABMD , ADM , AGIO , AKRX , ALE , AMCR , ARW , ASIX , AVP , BCE , BCPC , BLD , BLL , BPL , BPMC , BR , BSIG , CBRE , CI , CLVS , CLX , CNHI , CNQ , CNSL , CROX , CRS , CWT , DD , DEA , DLPH , DNKN , EIGI , EXC , GIL , GLOG , GM , GN...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
2024-07-29 07:15:06 ET Barclays analyst issues EQUAL-WEIGHT recommendation for BPMC on July 29, 2024 05:43AM ET. The previous analyst recommendation was Equal-Weight. BPMC was trading at $112.19 at issue of the analyst recommendation. The overall analyst consensus : BUY....
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $105.00 for BPMC on 2024-07-29 05:43:00. The adjusted price target was set to $105.00. At the time of the announcement, BPMC was trading at $112.19. The overall price target consensus is at $100.7...
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...